NanoViricides is trading at $1.52, up 7.04% now, extending gains after its September 15 announcement that the Phase II NV-387 oral-gummy Ebola trial is scheduled to start during the week of September 21 in the Democratic Republic of Congo.
- The trial targets Bundibugyo Ebola and other Ebola viruses amid an expanding outbreak, making the imminent clinical start the clearest company-specific catalyst.
- Broader risk sentiment is supportive, with major U.S. indices higher in pre-market trading.